Two Wall Street Analysts Predict Over 40% Upside for Argenx Shares
Argenx (NASDAQ: ARGX) has delivered strong performance over the past year, with a share price increase of about 30%. Two analysts from Wells Fargo and UBS are particularly bullish, forecasting more than 40% upside in the next 12 months. Their optimism is driven by Argenx's consistent revenue growth—now spanning 18 consecutive quarters—and recent strong financial results including nearly doubled earnings year-over-year. The company also achieved a significant milestone with positive Phase 3 trial data for Vyvgart Hytrulo in treating autoimmune myositis, marking the first statistically significant success in this indication. This adds to Argenx's growing track record of efficacy across four distinct autoimmune diseases and supports expectations for future growth through additional indications. Despite these positives, risks remain including over-reliance on its Vyvgart franchise and potential clinical setbacks from upcoming trials. However, the analysts' high price targets reflect confidence in continued commercial success and pipeline progress.
Tickers: $ARGX $UBS $WFC $WFC PRD
Topics: clinical trial results earnings report revenue growth stock performance